COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) have received an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $16.25.

A number of brokerages recently commented on CMPS. Weiss Ratings reissued a “sell (d-)” rating on shares of COMPASS Pathways in a research note on Wednesday. Royal Bank Of Canada increased their price target on shares of COMPASS Pathways from $16.00 to $21.00 and gave the company an “outperform” rating in a research report on Friday. Morgan Stanley raised their price objective on shares of COMPASS Pathways from $10.00 to $11.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. Finally, BTIG Research upped their target price on COMPASS Pathways from $7.00 to $14.00 and gave the company a “buy” rating in a research note on Monday, October 13th.

Institutional Trading of COMPASS Pathways

A number of large investors have recently made changes to their positions in CMPS. Simplify Asset Management Inc. acquired a new stake in COMPASS Pathways during the third quarter worth approximately $1,662,000. Bridger Management LLC purchased a new position in shares of COMPASS Pathways during the 2nd quarter worth $412,000. Schroder Investment Management Group acquired a new stake in shares of COMPASS Pathways during the second quarter worth $1,525,000. Stableford Capital II LLC acquired a new stake in shares of COMPASS Pathways during the second quarter worth $459,000. Finally, Hsbc Holdings PLC purchased a new stake in shares of COMPASS Pathways in the second quarter valued at $3,011,000. Institutional investors and hedge funds own 46.19% of the company’s stock.

COMPASS Pathways Stock Performance

CMPS opened at $7.17 on Friday. COMPASS Pathways has a 1-year low of $2.25 and a 1-year high of $8.20. The stock has a market cap of $688.46 million, a P/E ratio of -2.64 and a beta of 1.92. The stock’s 50 day simple moving average is $6.42 and its 200 day simple moving average is $5.58. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.23 and a quick ratio of 1.23.

COMPASS Pathways (NASDAQ:CMPS) last posted its earnings results on Tuesday, November 4th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.02. As a group, equities analysts anticipate that COMPASS Pathways will post -2.33 EPS for the current fiscal year.

About COMPASS Pathways

COMPASS Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, COMPASS Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.